Pseudallescheria boydii and its asexual form, Scedosporium apiospermum, are ubiquitous, saprophytic fungi that commonly cause cutaneous infection. However, in certain circumstances, P. boydii can also cause invasive disease, which can involve the central nervous system (CNS). When the CNS becomes involved, treatment is difficult, therapeutic options are limited, and the prognosis is poor. We report a case of Pseudallescheria brain abscess successfully treated with surgical drainage and systemic voriconazole, the first such case to be described in the literature. We also review previously reported cases of CNS pseudallescheriasis and evaluate therapeutic options.
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]. We present a case of a Pseudallescheria brain abscess successfully treated with surgical drainage and systemic voriconazole therapy, the first such case to be reported in the literature.
Case Report
A 59-year-old man with end-stage renal disease secondary to nephrosclerosis received a 5-antigen-mismatch cadaveric renal transplant on 31 May 1998. The immediate posttransplantation course was complicated by acute cellular rejection, which required increased immunosuppression.
Eleven weeks after undergoing transplantation, the patient awoke with right-arm paralysis. Cranial CT revealed a left frontoparietal contrast-enhancing lesion. Broad-spectrum antimicrobial therapy was initiated and a frontal craniotomy with evacuation of the abscess was performed. Histopathology revealed acutely branching hyphae with septa morphologically consistent with Aspergillus. Therapy with amphotericin B lipid complex (5 mg/kg/d) was then initiated. Despite those interventions, the patient's clinical status worsened as right-lowerextremity paresis and dysarthria developed. Cultures from the abscess subsequently yielded P. boydii. Miconazole (600 mg iv every 8 h) was then substituted for the amphotericin B, and the patient's neurological status stabilized. However, after 2 days of treatment with miconazole, the available supply was exhausted, and all efforts to obtain additional drug were futile.
Antifungal susceptibility testing performed at the University of Texas Health Science Center at San Antonio revealed MICs (mg/mL) of 116 for amphotericin B, 164 for flucytosine, 32 for fluconazole, and 0.25 for itraconazole. Antifungal therapy was changed to administration of itraconazole (200 mg po t.i.d. for 1 day as a loading dose, followed sequentially by 200 mg po b.i.d. for 10 days and then 400 mg po b.i.d. for 3 days). After that change in therapy, the patient's neurological status again worsened. Serial cranial imaging demonstrated progression of CNS disease.
At that point, we initiated therapy with voriconazole (which we obtained for compassionate use from Pfizer Pharmaceuticals [Groton, CT]; we monitored its safety as treatment with appropriate laboratory investigations). We administered a loading dose of 6 mg/kg iv every 12 h for 2 doses, followed by a maintenance dose of 4 mg/kg iv b.i.d., with a dose adjustment to 5 mg/kg for concurrent administration of phenytoin. Some neurological improvement was observed.
Fourteen days after initiation of voriconazole therapy, cranial imaging demonstrated stabilization of the intracranial abscess. A second craniotomy was then performed and the abscess was drained. Voriconazole therapy was continued intravenously until postoperative day 14, after the second evacuation. The patient was then given long-term suppressive therapy with oral voriconazole (400 mg po b.i.d.; the dosage was adjusted to 200 mg po b.i.d. following withdrawal of phenytoin).
During outpatient follow-up, the neurological deficits almost completely resolved. Following 12 months of therapy with voriconazole, there was neither clinical nor MRI evidence of residual infection. Antifungal therapy was therefore discontinued.
Literature Review
Cases of pseudallescherial CNS infection were identified through an extensive MEDLINE search of the Englishlanguage literature for the terms "Pseudallescheria," "scedosporium," "monosporium," "petriellidium," "apiospermum," and "boydii not shigella," as well as the term "fungi," cross-referenced with "CNS infection." All identified articles were reviewed. A bibliographic review was then performed on all related articles. Thirty-eight cases of culture-proven CNS pseudallescheriasis in addition to our own were identified . The median age of the infected patients was 33 years (range, 24 months to 69 years), and 76% of the cases resulted in death.
The most common clinical and radiographic presentation was either as a solitary mass or multiple brain abscesses (76.9%; table 1). Apparent risk factors for CNS pseudallescheriasis included medical immunosuppression and near-drowning episodes (table 2) . Of the 39 patients, 9 survived (24% of all patients; 32.1% of patients who received directed therapy) and 29 (76%) died; outcome was not reported for 1 case. Risk factors for acquisition of P. boydii did not appear to influence survival outcome.
Of the 9 survivors, 6 (66.6%) underwent surgical intervention, and 5 of those patients also received adjuvant antifungal therapy. Most patients for whom the outcome was successful received multiple antifungal agents in sequence; changes in therapy were presumably related to lack of therapeutic response (table 3). The final antifungal agent administered was miconazole for 4 survivors (2 received systemic plus intraventricular therapy and 2 received systemic therapy alone), ketoconazole for 2, amphotericin B for 1, and voriconazole for 1. One patient survived who was treated with surgical drainage alone, and 3 survived who were treated with antifungal therapy alone (ketoconazole, systemic miconazole, and systemic and intraventricular miconazole).
Of the 29 nonsurvivors, 9 (31.0%) underwent no directed antifungal therapy, in most cases because an appropriate diagnosis was not made before death. Of these 9, 1 did receive oral nystatin for oropharyngeal candidiasis and 1 underwent cranial irradiation for the misdiagnosis of lymphoma. Seven nonsurvivors (24.1%) underwent surgical intervention, 1 of whom underwent a subtotal resection secondary to abscess location (table 4). All but 1 of these 7 also received systemic antifungal chemotherapy. Sixteen nonsurvivors (55.2%) were treated with antifungal therapy alone.
Twelve patients underwent complete surgical drainage, and the survival rate in this subpopulation was 50%. Twenty-two of the 24 patients without surgical intervention were reported to have manifestations of CNS pseudallescheriasis that made surgical drainage difficult or impossible (meningitis, multiple abscesses, etc.). Only 3 (12.5%) of these 24 patients survived.
Discussion
Infection due to P. boydii presents both diagnostic and therapeutic challenges. Because of the organism's morphological Yes None [17] Yes Amphotericin B [24] No Miconazolerketoconazole [29] Yes Miconazole and intraventricular miconazole [30] Yes Ketoconazole [31] No Amphotericin Brmiconazolermiconazole and intraventricular miconazole [31] No Miconazole PR Yes Amphotericin Brmiconazoleritraconazolervoriconazole NOTE. PR, present report. Table 4 . Management of CNS pseudallescheriasis in nonsurvivors.
Reference Surgery Antifungal therapy [7] No Miconazole and intraventricular miconazole [8] No Amphotericin B [13] Yes None [18] No Amphotericin B and flucytosine [19] No Amphotericin B and miconazole [20] Yes Amphotericin Brmiconazole [23] No Amphotericin B and intrathecal amphotericin B [25] No Amphotericin Brketoconazoleramphotericin B and intrathecal amphotericin B [27] No Amphotericin Bramphotericin B and miconazole [28] Yes Itraconazole [31] Yes Miconazole and intra-abscess miconazole [31] Yes Amphotericin B [32] Yes a Amphotericin Brmiconazole [33] No Amphotericin B [34] Yes Amphotericin B and flucytosinersaperconazolersaperconazole and intraventricular amphotericin B [35] No Amphotericin B and flucytosine and intrathecal amphotericin B [37] No Amphotericin B [38] No Flucytosinerfluconazole [39] No Amphotericin B
NOTE. This table does not include patients receiving neither surgical intervention nor directed antifungal therapy.
a Patient underwent incomplete resection of abscess.
similarity to other filamentous fungi, histologic differentiation is difficult, and accurate diagnosis is thus dependent upon culture [5, 41] . Pseudallescheria and Scedosporium form slender, septate hyphae with parallel cell walls that cannot be reliably distinguished from Aspergillus species or Fusarium species unless conidia are present [5, 41] . When conidia are seen with appropriate hyphae, a preliminary diagnosis can be made but should be confirmed with fungal culture [5, 42] . Classically, the treatment of choice for pseudallescheriasis has been surgical resection with adjuvant antifungal therapy. Although surgical intervention is still the mainstay of treatment, the choice of antifungal therapy for P. boydii CNS infection is a challenging dilemma. Amphotericin B, a member of the polyene macrolide class of antibiotics, has long been the standard chemotherapeutic agent for severe invasive fungal disease. P. boydii, however, is generally resistant to amphotericin B; in vitro MICs are normally well beyond clinically achievable levels [43] [44] [45] . Amphotericin B also diffuses poorly into the CSF, which further complicates the treatment of CNS pseudallescheriasis [46] . Some authors have suggested that amphotericin B lipid complex may have clinically useful activity against Scedosporium [47] . However, only 2 patients are known to have received a course of amphotericin B lipid complex (ABELCET; The Liposome Company, Princeton, NJ) for documented P. boydii infection (neither of whom had CNS involvement), and neither demonstrated an adequate clinical response [48] . Thus, available data do not support the use of amphotericin B or its liposomal preparations in therapy for CNS pseudallescheriasis.
Miconazole, a phenethyl-imidazole derivative with significant associated toxicities, was previously the antifungal used in treatment of pseudallescherial infections [24, 49] , perhaps secondary to limited therapeutic options. Although miconazole has poor CNS penetration, it can be administered intrathecally [46] . Miconazole is no longer available in the United States and cannot be obtained, even for compassionate use.
Itraconazole, a triazole, and ketoconazole, an imidazole, have both been shown to have some efficacy against P. boydii [50] . Although in vitro susceptibilities are quite variable, there has been some clinical success with these agents when used in adjuvant therapy for cutaneous and pulmonary pseudallescherial infection [43, [51] [52] [53] . Itraconazole has only recently become available for iv administration, and ketoconazole remains available only as an oral preparation. The utility of these agents in the treatment of CNS infection is limited because they achieve poor drug concentrations in CSF and in brain tissue [1, 7, 46, 54] . CSF-to-serum concentrations of ketoconazole and itraconazole are !10% and !1%, respectively [55] . Although itraconazole has been shown to have some efficacy in the treatment of CNS cryptococcosis and coccidioidomycoses, the elimination half-life is much shorter in brain tissue than in plasma, which may significantly impair the therapeutic usefulness of itraconazole for CNS fungal infections [54] [55] [56] . Fluconazole, like itraconazole, is a triazole. Fluconazole diffuses well into the CSF [46] but is significantly less active against filamentous fungi than against yeast [1] .
Voriconazole is a triazole derivative developed through a series of structure-activity relationship analyses aimed at broadening the antifungal spectrum of fluconazole [57] . The in vitro activity of voriconazole is more potent than that of fluconazole against almost all fungi, especially molds but also Candida species that are typically resistant to fluconazole (e.g., C. krusei and C. glabrata) [58] . Several reports show that voriconazole MICs against P. boydii are consistently lower than MICs of any other antifungal agent [59] [60] [61] (table 5) .
Voriconazole is available for both iv and oral administration; oral bioavailability approaches 90% [62] . It is hepatically metabolized by the cytochrome P450 system. The serum half-life is 6 h [62] . Voriconazole is ∼60% protein-bound in serum and has a volume of distribution of 2L [62] . Because of its lipophilic Table 5 . Susceptibilities of Pseudallescheria boydii isolates to various antifungal agents, as reported in the literature.
Antifungal agent MIC (mg/mL) for isolates described in indicated reference [43] (n p 2) [44] (n p 6) [45] (n p 6) [59] (n p 5) [60] (n p 23) [61] (n p 6) nature, significant concentrations of voriconazole are achieved in CSF (50% of serum concentrations) and CNS tissues (2-fold higher than serum concentrations) [62] . The major potential toxic effects of voriconazole are hepatic and adaptive liver changes, including a dose-related increase in the level of alkaline phosphatase (Daniel Sheehan, Pfizer Pharmaceuticals, personal communication). The safety of receiving voriconazole during pregnancy has not been clearly defined. Because of its metabolism by the P450 system and its relatively high degree of protein-binding, dose adjustments are required if voriconazole is administered concurrently with phenytoin and rifabutin, which decrease voriconazole levels, or with erythromycin, ritonavir, delavirdine, and omeprazole, which increase voriconazole levels (Daniel Sheehan, personal communication). Voriconazole use may also result in increased levels of cyclosporin, tacrolimus, and warfarin (Daniel Sheehan, personal communication).
Currently, limited data are available on the clinical efficacy of voriconazole against P. boydii. Girmenia et al. [43] reported a case of disseminated cutaneous Pseudallescheria infection that responded well to voriconazole, although the patient died of other complicating factors. Jabado et al. [51] reported a case of pulmonary pseudallescheriasis successfully treated with surgery, systemic voriconazole, and IFN-g. Classically, the prognosis for patients with Pseudallescheria CNS infections is poor, even when early and aggressive therapeutic interventions are undertaken. We have presented a case of CNS pseudallescheriasis in which aggressive surgical intervention and adjuvant antifungal therapy with voriconazole resulted in the patient's survival with minimal neurological sequelae. Surgical drainage, when possible, is clearly the key therapeutic intervention. However, the choice of antifungal agent remains a challenge. Our case suggests that voriconazole may be the agent with the best combination of antipseudallescherial activity and CNS penetration. Although voriconazole is not yet available for general use, it offers promise for future therapy for currently difficult-to-treat and/or resistant fungal infections such as pseudallescheriasis.
